Treatment of hidradenitis suppurativa using JAK inhibitors
By administering selective JAK1 and/or JAK2 inhibitors, the method effectively treats hidradenitis suppurativa by modulating immune and inflammatory pathways, providing substantial clinical improvements.
AU2024219822B2Pending Publication Date: 2026-07-16INCYTE CORP
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- INCYTE CORP
- Filing Date
- 2024-09-18
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
Current treatments for hidradenitis suppurativa are limited, and there is a need for new pharmaceuticals that can effectively modulate the immune and inflammatory pathways to address this condition.
Method used
Administering therapeutically effective amounts of compounds that inhibit Janus kinase 1 (JAK1) and/or JAK2, or their pharmaceutically acceptable salts, which are selective over JAK3 and TYK2, to treat hidradenitis suppurativa.
Benefits of technology
The use of JAK1 and/or JAK2 inhibitors, such as ruxolitinib, leads to significant improvements in hidradenitis suppurativa clinical response, reducing inflammation and improving symptoms.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000070_0000 
Figure 00000071_0000 
Figure 00000072_0000
Abstract
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and / or JAK2, or a 5 pharmaceutically acceptable salt thereof. 20 24 21 98 22 18 S ep 2 02 4 A B S T R A C T 2 0 2 4 2 1 9 8 2 2 1 8 S e p 2 0 2 4 5
Need to check novelty before this filing date? Find Prior Art